跳至主要内容
临床试验/NCT07613645
NCT07613645招募中不适用

Diet for Prevention of Recurrent C. Difficile Infection

University of Michigan1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年6月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
1

研究概览

简要总结

This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling. Counseling visits will be by phone or online videoconference (e.g. Zoom). Meals will be provided for two weeks and then participants will be asked to continue similar meals for 6 more weeks.

Participants will provide responses to questionnaires and multiple stool samples over the course of the study. The goal is to understand how different health factors might impact the risk of becoming infected again with C. difficile in the future.

Of note, this study will conceal the intervention details (type of diets) so that the control group does not increase their intake with the particular diet during the study. Participants in the control arm will be unblinded at the end of the study during a debrief with a member of the study team. At that time participants will be informed of diet being tested.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

盲法说明

The type of diet will be masked to the health counseling group.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Non-recurrent non-fulminant CDI (laboratory-confirmed C. difficile infection without prior C. difficile infection within 3 months and no shock, hypotension, ileus, or megacolon)
  • Currently receiving treatment or with plan to initiate treatment for CDI
  • CDI treatment with standard regimen (fidaxomicin 200milligrams (mg) by mouth (PO) twice a day x 10-14 days or vancomycin 125mg PO 4 x a day (QID) x 10-14 days)
  • No prior advanced therapy for C. difficile (i.e. prolonged antibiotic therapy, bezlotoxumab, fecal transplant, other microbial therapy)

排除标准

  • Chemotherapy, immunotherapy, or transplant within 12 months
  • Colon not in continuity (i.e. status post total colectomy or with current ileostomy)
  • Medical comorbidities requiring specific fluid, sodium, or protein intake level outside range of prepared diet options
  • Baseline diet with > 11grams fiber/1000 kilocalories
  • Low sodium diet, vegan diet, gluten-free diet, Kosher diet or any other diet not able to be accommodated by the metabolic kitchen
  • Allergies, food preferences, or other restrictions not able to be accommodated by the metabolic (note: lactose intolerance will not impact eligibility)
  • Unwilling to stop probiotic supplements during the study period
  • Current antibiotic therapy that will continue after CDI treatment has finished
  • Hospitalized or in skilled nursing facility at time of CDI treatment conclusion
  • Pregnancy or breast-feeding
  • Unable to provide a stool sample of appropriate quality for further analysis (i.e. low volume, adulterated, delayed return, etc.)

研究组 & 干预措施

Diet (control diet per protocol) plus health counseling

Other

As stated earlier, the diet and intervention details will not be listed for concealment purposes.

干预措施: Health counseling sessions (Other)

Experimental Diet plus health counseling

Experimental

As stated earlier, the diet and intervention details will not be listed for concealment purposes.

干预措施: Diet (experimental diet) (Other)

Diet (control diet per protocol) plus health counseling

Other

As stated earlier, the diet and intervention details will not be listed for concealment purposes.

干预措施: Diet (control diet) (Other)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kira Newman

Assistant Professor of Internal Medicine

University of Michigan

研究点 (1)

Loading locations...

相似试验